Supplementary Tables 1-4, Figure 1 from The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt; and Exhibits a Narrow Resistance Profile